1. Scrip
  2. >>ESG
  3. >>Diversity & Inclusion

How Gilead Did Trial Diversity Before It Was Cool

 
• By Alaric DeArment

Thanks in part to its HIV focus, Gilead was an early adopter when it came to emphasizing diversity in trials.

Gilead highlighted trial diversity efforts at a recent ESG event • Source: Shutterstock

Gilead Sciences, Inc. notes it was an early adopter when it comes to trial diversity because of its historic focus on HIV. But its development of Veklury (remdesivir) brought it into the spotlight when The New England Journal of Medicine published an article in August 2020 highlighting disproportionate enrollment of white participants in the National Institutes of Health’s early trials of the COVID-19 antiviral. That article helped jumpstart the biopharma industry’s current focus on clinical trial diversity.

The Foster City, CA-based biotech highlighted some of its focus on trial diversity in a 3 October session at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 
• By Anju Ghangurde

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

More from ESG

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 
• By Mary Jo Laffler

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Why Global Pull Incentives Matter For AMR Drugs

 
• By Lisa Takagi

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 
• By Mary Jo Laffler

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.